{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:10:44Z","timestamp":1786997444310,"version":"build-2736575974"},"reference-count":88,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T00:00:00Z","timestamp":1653004800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008497","name":"Boston Scientific Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008497","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.thromres.2022.05.009","type":"journal-article","created":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T11:29:48Z","timestamp":1653046188000},"page":"41-51","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Hemostatic biomarkers and antithrombotic strategy in percutaneous left atrial interventions: State-of-the-art review"],"prefix":"10.1016","volume":"215","author":[{"given":"Errol W.","family":"Aarnink","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina F.M.","family":"Huijboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem L.","family":"Bor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moniek","family":"Maarse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai L.","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Ten Cate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurri\u00ebn M.","family":"Ten Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas V.A.","family":"Boersma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.thromres.2022.05.009_bb0005","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/0003-4975(95)00887-X","article-title":"Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation","volume":"61","author":"Blackshear","year":"1996","journal-title":"Ann. Thorac. Surg."},{"issue":"20","key":"10.1016\/j.thromres.2022.05.009_bb0010","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1001\/jama.2021.4359","article-title":"Preliminary investigation of in situ thrombus within patent foramen ovale in patients with and without stroke","volume":"325","author":"Yan","year":"2021","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.thromres.2022.05.009_bb0015","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMoa1705915","article-title":"Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke","volume":"377","author":"Mas","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.thromres.2022.05.009_bb0020","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1056\/NEJMoa1610057","article-title":"Long-term outcomes of patent foramen ovale closure or medical therapy after stroke","volume":"377","author":"Saver","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.thromres.2022.05.009_bb0025","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1056\/NEJMoa1707404","article-title":"Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke","volume":"377","author":"Sondergaard","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"10.1016\/j.thromres.2022.05.009_bb0030","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1016\/j.jacc.2017.10.021","article-title":"5-year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF trials","volume":"70","author":"Reddy","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"issue":"25","key":"10.1016\/j.thromres.2022.05.009_bb0035","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1016\/j.jacc.2020.04.067","article-title":"Left atrial appendage closure versus direct oral anticoagulants in high-risk patients with atrial fibrillation","volume":"75","author":"Osmancik","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"issue":"Suppl 1","key":"10.1016\/j.thromres.2022.05.009_bb0040","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1111\/jth.12961","article-title":"Medical device-induced thrombosis: what causes it and how can we prevent it?","volume":"13","author":"Jaffer","year":"2015","journal-title":"J. Thromb. Haemost."},{"issue":"7","key":"10.1016\/j.thromres.2022.05.009_bb0045","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.jcin.2014.03.003","article-title":"Impact of Watchman and Amplatzer devices on left atrial appendage adjacent structures and healing response in a canine model","volume":"7","author":"Kar","year":"2014","journal-title":"J. Am. Coll. Cardiol. Intv."},{"issue":"5","key":"10.1016\/j.thromres.2022.05.009_bb0050","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1161\/01.CIR.79.5.1091","article-title":"Transcatheter closure of atrial septal defects. Experimental studies","volume":"79","author":"Lock","year":"1989","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.thromres.2022.05.009_bb0055","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.jcin.2010.04.017","article-title":"Left atrial appendage obliteration: mechanisms of healing and intracardiac integration","volume":"3","author":"Schwartz","year":"2010","journal-title":"J. Am. Coll. Cardiol. Intv."},{"issue":"9","key":"10.1016\/j.thromres.2022.05.009_bb0060","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1161\/CIRCULATIONAHA.118.035090","article-title":"Device-related thrombus after left atrial appendage closure: incidence, predictors, and outcomes","volume":"138","author":"Dukkipati","year":"2018","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.thromres.2022.05.009_bb0065","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.118.006841","article-title":"Evaluating real-world clinical outcomes in atrial fibrillation patients receiving the WATCHMAN left atrial appendage closure technology: final 2-year outcome data of the EWOLUTION trial focusing on history of stroke and hemorrhage","volume":"12","author":"Boersma","year":"2019","journal-title":"Circ. Arrhythm. Electrophysiol."},{"issue":"7","key":"10.1016\/j.thromres.2022.05.009_bb0070","first-page":"1123","article-title":"Short and long term complications of device closure of atrial septal defect and patent foramen ovale: meta-analysis of 28,142 patients from 203 studies","volume":"82","author":"Abaci","year":"2013","journal-title":"Catheter. Cardiovasc. Interv."},{"issue":"3","key":"10.1016\/j.thromres.2022.05.009_bb0075","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.amjcard.2017.04.046","article-title":"Left atrial appendage occlusion in patients with atrial fibrillation and previous major gastrointestinal bleeding (from the Amplatzer cardiac plug multicenter Registry)","volume":"120","author":"Lempereur","year":"2017","journal-title":"Am. J. Cardiol."},{"issue":"12","key":"10.1016\/j.thromres.2022.05.009_bb0080","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/j.jacep.2018.09.007","article-title":"Incidence and clinical impact of device-related thrombus following percutaneous left atrial appendage occlusion: a meta-analysis","volume":"4","author":"Alkhouli","year":"2018","journal-title":"JACC Clin Electrophysiol."},{"issue":"4","key":"10.1016\/j.thromres.2022.05.009_bb0085","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jcin.2016.11.029","article-title":"Incidence and clinical impact of device-associated thrombus and peri-device leak following left atrial appendage closure with the Amplatzer cardiac plug","volume":"10","author":"Saw","year":"2017","journal-title":"JACC Cardiovasc Interv."},{"issue":"14","key":"10.1016\/j.thromres.2022.05.009_bb0090","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1016\/j.jacc.2018.01.076","article-title":"Device-related thrombosis after percutaneous left atrial appendage occlusion for atrial fibrillation","volume":"71","author":"Fauchier","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"issue":"7","key":"10.1016\/j.thromres.2022.05.009_bb0095","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.amjcard.2016.01.039","article-title":"Assessment of device-related thrombus and associated clinical outcomes with the WATCHMAN left atrial appendage closure device for embolic protection in patients with atrial fibrillation (from the PROTECT-AF Trial)","volume":"117","author":"Main","year":"2016","journal-title":"Am. J. Cardiol."},{"issue":"11","key":"10.1016\/j.thromres.2022.05.009_bb0100","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.jcin.2019.02.003","article-title":"Incidence, characterization, and clinical impact of device-related thrombus following left atrial appendage occlusion in the prospective global AMPLATZER amulet observational study","volume":"12","author":"Aminian","year":"2019","journal-title":"JACC Cardiovasc. Interv."},{"issue":"4","key":"10.1016\/j.thromres.2022.05.009_bb0105","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.amjcard.2003.10.036","article-title":"Incidence of thrombus formation on the CardioSEAL and the Amplatzer interatrial closure devices","volume":"93","author":"Anzai","year":"2004","journal-title":"Am. J. Cardiol."},{"issue":"1","key":"10.1016\/j.thromres.2022.05.009_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2014.04.029","article-title":"Prospective randomized evaluation of the Watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial","volume":"64","author":"Holmes","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"issue":"9689","key":"10.1016\/j.thromres.2022.05.009_bb0115","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/S0140-6736(09)61343-X","article-title":"Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial","volume":"374","author":"Holmes","year":"2009","journal-title":"Lancet (London, England)."},{"issue":"12","key":"10.1016\/j.thromres.2022.05.009_bb0120","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1056\/NEJMoa1301440","article-title":"Closure of patent foramen ovale versus medical therapy after cryptogenic stroke","volume":"368","author":"Carroll","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"25","key":"10.1016\/j.thromres.2022.05.009_bb0125","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.21.7752","article-title":"D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna cancer and thrombosis study","volume":"27","author":"Ay","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.thromres.2022.05.009_bb0130","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/0268-960X(90)90014-J","article-title":"Assessment of hypercoagulable states by measurement of activation fragments and peptides","volume":"4","author":"Boisclair","year":"1990","journal-title":"Blood Rev."},{"issue":"2","key":"10.1016\/j.thromres.2022.05.009_bb0135","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1182\/blood.V70.2.343.343","article-title":"The pathophysiology of the prethrombotic state in humans: insights gained from studies using markers of hemostatic system activation","volume":"70","author":"Bauer","year":"1987","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.thromres.2022.05.009_bb0140","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1182\/blood.V59.5.1086.1086","article-title":"Studies of the prothrombin activation pathway utilizing radioimmunoassays for the F2\/F1 + 2 fragment and thrombin\u2013antithrombin complex","volume":"59","author":"Teitel","year":"1982","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.thromres.2022.05.009_bb0145","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.120.009039","article-title":"Short-term Oral anticoagulation versus antiplatelet therapy following transcatheter left atrial appendage closure","volume":"13","author":"Asmarats","year":"2020","journal-title":"Circ Cardiovasc Interv."},{"issue":"1","key":"10.1016\/j.thromres.2022.05.009_bb0150","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.amjcard.2017.03.253","article-title":"Changes in coagulation and platelet activation markers following transcatheter left atrial appendage closure","volume":"120","author":"Rod\u00e9s-Cabau","year":"2017","journal-title":"Am. J. Cardiol."},{"issue":"7","key":"10.1016\/j.thromres.2022.05.009_bb0155","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.119.008481","article-title":"Reduced rivaroxaban dose versus dual antiplatelet therapy after left atrial appendage closure: ADRIFT a randomized pilot study","volume":"13","author":"Duthoit","year":"2020","journal-title":"Circ Cardiovasc Interv."},{"issue":"1","key":"10.1016\/j.thromres.2022.05.009_bb0160","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1161\/01.STR.0000251712.55322.69","article-title":"Enhanced thrombogenesis but not platelet activation is associated with transcatheter closure of patent foramen ovale in patients with cryptogenic stroke","volume":"38","author":"B\u00e9dard","year":"2007","journal-title":"Stroke"},{"issue":"1","key":"10.1016\/j.thromres.2022.05.009_bb0165","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ijcard.2004.03.022","article-title":"Assessment of the markers of platelet and coagulation activation following transcatheter closure of atrial septal defects","volume":"98","author":"Rod\u00e9s-Cabau","year":"2005","journal-title":"Int. J. Cardiol."},{"issue":"7","key":"10.1016\/j.thromres.2022.05.009_bb0170","doi-asserted-by":"crossref","first-page":"E6","DOI":"10.1002\/clc.20752","article-title":"Enhanced prothrombin formation and platelet activation in chinese patients after transcatheter closure of atrial septal defect","volume":"33","author":"Zeng","year":"2010","journal-title":"Clin. Cardiol."},{"issue":"8","key":"10.1016\/j.thromres.2022.05.009_bb0175","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.jacc.2004.12.071","article-title":"Platelet P-selectin plays an important role in arterial thrombogenesis by forming large stable platelet-leukocyte aggregates","volume":"45","author":"Yokoyama","year":"2005","journal-title":"J. Am. Coll. Cardiol."},{"issue":"4","key":"10.1016\/j.thromres.2022.05.009_bb0180","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.molmed.2004.02.007","article-title":"A new role in hemostasis for the adhesion receptor P-selectin","volume":"10","author":"Cambien","year":"2004","journal-title":"Trends Mol. Med."},{"issue":"6","key":"10.1016\/j.thromres.2022.05.009_bb0185","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1055\/s-0038-1656116","article-title":"The origin of P-selectin as a circulating plasma protein","volume":"77","author":"Fijnheer","year":"1997","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2022.05.009_bb0190","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.684920","article-title":"Soluble platelet release factors as biomarkers for cardiovascular disease","volume":"8","author":"Baidildinova","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"issue":"12","key":"10.1016\/j.thromres.2022.05.009_bb0195","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJMoa022600","article-title":"Soluble CD40 ligand in acute coronary syndromes","volume":"348","author":"Heeschen","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.thromres.2022.05.009_bb0200","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1046\/j.1365-2141.1998.00883.x","article-title":"Low-dose aspirin does not lower in vivo platelet activation in healthy smokers","volume":"102","author":"Pernerstorfer","year":"1998","journal-title":"Br. J. Haematol."},{"issue":"12","key":"10.1016\/j.thromres.2022.05.009_bb0205","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1089\/gtmb.2014.0206","article-title":"Platelet activation through the efficacy of aspirin in congenital heart disease patients undergoing transcatheter closure of atrial septal defects or ventricular septal defects","volume":"18","author":"Pan","year":"2014","journal-title":"Genet. Test Mol. Biomarkers"},{"issue":"4","key":"10.1016\/j.thromres.2022.05.009_bb0210","doi-asserted-by":"crossref","first-page":"165","DOI":"10.5830\/CVJA-2014-027","article-title":"Decline in mean platelet volume in patients with patent foramen ovale undergoing percutaneous closure","volume":"25","author":"D\u00fczel","year":"2014","journal-title":"Cardiovasc. J. Afr."},{"issue":"12","key":"10.1016\/j.thromres.2022.05.009_bb0215","doi-asserted-by":"crossref","first-page":"870","DOI":"10.2459\/JCM.0000000000000217","article-title":"Enhanced platelet activity in atrial septal defect","volume":"17","author":"Kaya","year":"2016","journal-title":"J. Cardiovasc. Med. (Hagerstown)"},{"issue":"4","key":"10.1016\/j.thromres.2022.05.009_bb0220","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1080\/AC.68.4.2988890","article-title":"Decline in platelet count after percutaneous transcatheter closure of congenital heart disease","volume":"68","author":"Zhou","year":"2013","journal-title":"Acta Cardiol."},{"issue":"4","key":"10.1016\/j.thromres.2022.05.009_bb0225","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10040615","article-title":"Quantitative and qualitative platelet derangements in cardiac surgery and extracorporeal life support","volume":"10","author":"Squiccimarro","year":"2021","journal-title":"J. Clin. Med."},{"issue":"6","key":"10.1016\/j.thromres.2022.05.009_bb6000","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.thromres.2012.09.001","article-title":"Occurrence and clinical significance of in-hospital acquired thrombocytopenia in patients undergoing transcatheter device closure for congenital heart defect","volume":"130","author":"Li","year":"2012","journal-title":"Thromb. Res."},{"issue":"6","key":"10.1016\/j.thromres.2022.05.009_bb0230","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jcin.2013.02.014","article-title":"Risk factors for thrombus formation on the Amplatzer cardiac plug after left atrial appendage occlusion","volume":"6","author":"Plicht","year":"2013","journal-title":"JACC Cardiovasc. Interv."},{"issue":"4","key":"10.1016\/j.thromres.2022.05.009_bb0235","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1160\/TH11-09-0673","article-title":"Procoagulant activity of erythrocytes and platelets through phosphatidylserine exposure and microparticles release in patients with nephrotic syndrome","volume":"107","author":"Gao","year":"2012","journal-title":"Thromb. Haemost."},{"issue":"06","key":"10.1016\/j.thromres.2022.05.009_bb0240","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1160\/TH12-11-0811","article-title":"Role of erythrocytes and platelets in the hypercoagulable status in polycythemia vera through phosphatidylserine exposure and microparticle generation","volume":"109","author":"Tan","year":"2013","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2022.05.009_bb0245","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ijcard.2019.10.026","article-title":"Impact of left atrial appendage closure on circulating microvesicles levels: the MICROPLUG study","volume":"307","author":"Amabile","year":"2020","journal-title":"Int. J. Cardiol."},{"issue":"2","key":"10.1016\/j.thromres.2022.05.009_bb0250","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.thromres.2015.06.015","article-title":"Procoagulant activity induced by transcatheter closure of atrial septal defects is associated with exposure of phosphatidylserine on microparticles, platelets and red blood cells","volume":"136","author":"Ding","year":"2015","journal-title":"Thromb. Res."},{"issue":"1","key":"10.1016\/j.thromres.2022.05.009_bb0255","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1365-2141.2011.08793.x","article-title":"Guidelines for the laboratory investigation of heritable disorders of platelet function","volume":"155","author":"Harrison","year":"2011","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.thromres.2022.05.009_bb0260","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ijcard.2018.10.040","article-title":"Antiplatelet effects of aspirin and clopidogrel after left atrial appendage (LAA) occluder implantation","volume":"275","author":"Dannenberg","year":"2019","journal-title":"Int. J. Cardiol."},{"issue":"3","key":"10.1016\/j.thromres.2022.05.009_bb0265","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1007\/s11239-020-02205-5","article-title":"Detailed thrombogenicity phenotyping and 1 year outcomes in patients undergoing WATCHMAN implantation: (TARGET-WATCHMAN) a case-control study","volume":"50","author":"Sherwood","year":"2020","journal-title":"J. Thromb. Thrombolysis"},{"issue":"4","key":"10.1016\/j.thromres.2022.05.009_bb0270","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3109\/09537104.2015.1096335","article-title":"Antiplatelet effects of clopidogrel and aspirin after interventional patent foramen ovale\/ atrium septum defect closure","volume":"27","author":"Polzin","year":"2016","journal-title":"Platelets"},{"issue":"10","key":"10.1016\/j.thromres.2022.05.009_bb0275","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1055\/s-0039-1694751","article-title":"Thrombogenicity and antithrombotic strategies in structural heart interventions and nonaortic cardiac device therapy-current evidence and practice","volume":"119","author":"Geisler","year":"2019","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2022.05.009_bb0280","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.peptides.2018.10.002","article-title":"Endothelin and the heart in health and diseases","volume":"111","author":"Miyauchi","year":"2019","journal-title":"Peptides"},{"issue":"8","key":"10.1016\/j.thromres.2022.05.009_bb0285","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1111\/j.1538-7836.2005.01420.x","article-title":"PAI-1 and atherothrombosis","volume":"3","author":"Vaughan","year":"2005","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2022.05.009_bb0290","article-title":"Role of homocysteine in the development of cardiovascular disease","author":"Ganguly","year":"2015146","journal-title":"Nutr. J."},{"issue":"3","key":"10.1016\/j.thromres.2022.05.009_bb0295","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/joic.12383","article-title":"Impaired endothelial function in patients with cryptogenic stroke and patent foramen ovale is not affected by closure","volume":"30","author":"Lantz","year":"2017","journal-title":"J. Interv. Cardiol."},{"issue":"4","key":"10.1016\/j.thromres.2022.05.009_bb0300","doi-asserted-by":"crossref","first-page":"569","DOI":"10.5858\/arpa.2016-0088-OA","article-title":"New-generation thromboelastography: comprehensive evaluation of citrated and heparinized blood sample storage effect on clot-forming variables","volume":"141","author":"Dias","year":"2017","journal-title":"Arch. Pathol. Lab. Med."},{"issue":"1","key":"10.1016\/j.thromres.2022.05.009_bb0305","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jacep.2016.05.006","article-title":"Thrombus formation after left atrial appendage occlusion with the amplatzer amulet device","volume":"3","author":"Sedaghat","year":"2017","journal-title":"JACC Clin. Electrophysiol."},{"issue":"2","key":"10.1016\/j.thromres.2022.05.009_bb0310","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jacc.2003.10.030","article-title":"Incidence and clinical course of thrombus formation on atrial septal defect and patient foramen ovale closure devices in 1,000 consecutive patients","volume":"43","author":"Krumsdorf","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"issue":"2","key":"10.1016\/j.thromres.2022.05.009_bb0315","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1213\/ANE.0b013e31823a088c","article-title":"Procoagulant activity in hemostasis and thrombosis: Virchow's triad revisited","volume":"114","author":"Wolberg","year":"2012","journal-title":"Anesth. Analg."},{"issue":"8","key":"10.1016\/j.thromres.2022.05.009_bb0320","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1016\/S0142-9612(01)00304-0","article-title":"Effect of biologically active coating on biocompatibility of nitinol devices designed for the closure of intra-atrial communications","volume":"23","author":"Kong","year":"2002","journal-title":"Biomaterials"},{"issue":"10","key":"10.1016\/j.thromres.2022.05.009_bb0325","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1166\/jbt.2016.1507","article-title":"Facile surface modification of nitinol with dopamine-conjugated hyaluronic acid for improving blood compatibility","volume":"6","author":"Lih","year":"2016","journal-title":"J. Biomater. Tissue Eng."},{"issue":"8\u20139","key":"10.1016\/j.thromres.2022.05.009_bb0330","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.acvd.2020.03.022","article-title":"In vitro comparison of three percutaneous atrial septal defect closure devices for endothelialisation and haemocompatibility","volume":"113","author":"Levy","year":"2020","journal-title":"Arch. Cardiovasc. Dis."},{"key":"10.1016\/j.thromres.2022.05.009_bb0335","article-title":"Amulet or Watchman device for percutaneous left atrial appendage closure: primary results of the SWISS-APERO randomized clinical trial","author":"Galea","year":"2021","journal-title":"Circulation"},{"issue":"19","key":"10.1016\/j.thromres.2022.05.009_bb0340","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1161\/CIRCULATIONAHA.121.057063","article-title":"Amplatzer amulet left atrial appendage occluder versus Watchman device for stroke prophylaxis (Amulet IDE): a randomized, controlled trial","volume":"144","author":"Lakkireddy","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2022.05.009_bb0345","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ijcard.2019.09.053","article-title":"Coagulation factors and fibrinolytic activity in the left atrial appendage and other heart chambers in patients with atrial fibrillation: is there a local intracardiac prothrombotic state? (HEART-CLOT study)","volume":"301","author":"Bartus","year":"2020","journal-title":"Int. J. Cardiol."},{"issue":"7","key":"10.1016\/j.thromres.2022.05.009_bb0350","doi-asserted-by":"crossref","DOI":"10.1161\/STROKEAHA.106.480715","article-title":"Enhanced thrombogenesis is physiologic after transcatheter closure of patent foramen ovale","volume":"38","author":"Giardini","year":"2007","journal-title":"Stroke"},{"issue":"11","key":"10.1016\/j.thromres.2022.05.009_bb0355","doi-asserted-by":"crossref","DOI":"10.1177\/0300060520966478","article-title":"Meta-analysis of postoperative antithrombotic therapy after left atrial appendage occlusion","volume":"48","author":"Li","year":"2020","journal-title":"J. Int. Med. Res."},{"issue":"11","key":"10.1016\/j.thromres.2022.05.009_bb0360","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.jcin.2019.04.004","article-title":"Propensity-matched comparison of Oral anticoagulation versus antiplatelet therapy after left atrial appendage closure with WATCHMAN","volume":"12","author":"Sondergaard","year":"2019","journal-title":"JACC Cardiovasc. Interv."},{"key":"10.1016\/j.thromres.2022.05.009_bb0365","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ijcard.2021.02.054","article-title":"Short-term direct oral anticoagulation or dual antiplatelet therapy following left atrial appendage closure in patients with relative contraindications to chronic anticoagulation therapy","volume":"333","author":"Faroux","year":"2021","journal-title":"Int. J. Cardiol."},{"issue":"21","key":"10.1016\/j.thromres.2022.05.009_bb0370","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/j.jcin.2021.07.031","article-title":"Half-dose direct Oral anticoagulation versus standard antithrombotic therapy after left atrial appendage occlusion","volume":"14","author":"Della Rocca","year":"2021","journal-title":"JACC Cardiovasc. Interv."},{"issue":"6","key":"10.1016\/j.thromres.2022.05.009_bb0375","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1093\/eurheartj\/ehaa554","article-title":"2020 ESC guidelines for the management of adult congenital heart disease","volume":"42","author":"Baumgartner","year":"2021","journal-title":"Eur. Heart J."},{"issue":"2","key":"10.1016\/j.thromres.2022.05.009_bb0380","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s10840-020-00884-x","article-title":"Rationale and design of a randomized clinical trial to compare two antithrombotic strategies after left atrial appendage occlusion: double antiplatelet therapy vs. apixaban (ADALA study)","volume":"59","author":"Flores-Umanzor","year":"2020","journal-title":"J. Interv. Card. Electrophysiol."},{"issue":"11","key":"10.1016\/j.thromres.2022.05.009_bb0385","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1056\/NEJMoa1009639","article-title":"Closure or medical therapy for cryptogenic stroke with patent foramen ovale","volume":"366","author":"Furlan","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"10.1016\/j.thromres.2022.05.009_bb0390","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1161\/CIRCULATIONAHA.121.054305","article-title":"Antithrombotic therapy in patients undergoing transcatheter interventions for structural heart disease","volume":"144","author":"Calabr\u00f2","year":"2021","journal-title":"Circulation"},{"issue":"19","key":"10.1016\/j.thromres.2022.05.009_bb0395","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1136\/heartjnl-2020-316977","article-title":"Atrial fibrillation and the prothrombotic state: revisiting Virchow's triad in 2020","volume":"106","author":"Ding","year":"2020","journal-title":"Heart"},{"issue":"18","key":"10.1016\/j.thromres.2022.05.009_bb0400","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1161\/CIRCULATIONAHA.120.050117","article-title":"Primary outcome evaluation of a next-generation left atrial appendage closure device: results from the PINNACLE FLX trial","volume":"143","author":"Kar","year":"2021","journal-title":"Circulation"},{"issue":"30","key":"10.1016\/j.thromres.2022.05.009_bb0405","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1093\/eurheartj\/ehaa169","article-title":"Left atrial appendage occlusion with the Amplatzer\u2122 Amulet\u2122 device: full results of the prospective global observational study","volume":"41","author":"Hildick-Smith","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.thromres.2022.05.009_bb0410","article-title":"The impact of dabigatran and rivaroxaban on variation of platelet activation biomarkers and DRT following percutaneous left atrial appendage closure","volume":"12","author":"Li","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"5","key":"10.1016\/j.thromres.2022.05.009_bb0415","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jcin.2020.01.226","article-title":"Derivation, validation, and prognostic utility of a prediction rule for nonresponse to clopidogrel: the ABCD-GENE score","volume":"13","author":"Angiolillo","year":"2020","journal-title":"JACC Cardiovasc. Interv."},{"issue":"3","key":"10.1016\/j.thromres.2022.05.009_bb0420","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1161\/CIRCULATIONAHA.119.040167","article-title":"Defining high bleeding risk in patients undergoing percutaneous coronary intervention","volume":"140","author":"Urban","year":"2019","journal-title":"Circulation"},{"issue":"27","key":"10.1016\/j.thromres.2022.05.009_bb0425","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1093\/eurheartj\/ehv104","article-title":"Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention","volume":"36","author":"Aradi","year":"2015","journal-title":"Eur. Heart J."},{"issue":"1","key":"10.1016\/j.thromres.2022.05.009_bb0430","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/ehjcvp\/pvw026","article-title":"Determinants of agreement between proposed therapeutic windows of platelet function tests in vulnerable patients","volume":"3","author":"Vries","year":"2017","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"issue":"17","key":"10.1016\/j.thromres.2022.05.009_bb0435","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1907096","article-title":"A genotype-guided strategy for oral P2Y12 inhibitors in primary PCI","volume":"381","author":"DMF","year":"2019","journal-title":"N. Engl. J. Med."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384822002754?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384822002754?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:48:06Z","timestamp":1758736086000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384822002754"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":88,"alternative-id":["S0049384822002754"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2022.05.009","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hemostatic biomarkers and antithrombotic strategy in percutaneous left atrial interventions: State-of-the-art review","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2022.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}